Research at Pathios Therapeutics Ltd. has led to the identification of tricyclic psychosine receptor (GPR65) antagonists reported to be useful for the treatment of cancer, asthma, acute respiratory distress syndrome, chronic obstructive pulmonary disease and autoimmune diseases.
A recent Glaxosmithlline Intellectual Property (No 4) Ltd. and Ideaya Biosciences Inc. patent describes the development of thiadiazolyl derivatives acting as DNA polymerase θ (POLQ) inhibitors reported to be useful for the treatment of cancer.
Researchers from Etern Biopharma (Shanghai) Co. Ltd. recently reported the discovery and preclinical characterization of ETS-003, a novel YAP/TAZ-TEAD protein-protein interaction (PPI) inhibitor, being developed for the treatment of cancer.
It is known that the Hippo/YAP signaling pathway plays a crucial role in cell proliferation and tumorigenesis; is thought to contribute to 10% of all cancer types. TYK Medicines Inc. has presented a novel YAP/TEAD interaction inhibitor compound, TY-1054, as a potential approach for treating cancer with dysregulated Hippo/YAP pathway.
Cancer immunotherapy candidate BSI-508, a bispecific fusion molecule targeting PD-1 and CD47, is undergoing early development at Biosion Inc., who recently presented preclinical data on the product.
Researchers based at Uppsala University in Sweden have created an adeno-associated viral (AAV) vector treatment for glioma or glioblastoma that extended survival in a mouse model of the brain cancer. Writing in the May 11, 2023, issue of Cancer Cell, the researchers reported that by introducing an inflammatory protein known as LIGHT to the tumor microenvironment using the AAV treatment, the mice were better able to fight the cancer.
The U.S. FDA issued a complete response letter regarding the BLA for Immunitybio Inc.’s bladder cancer treatment, N-803 (Anktiva), halting the drug’s development and slicing the stock value in half. The problems stem from the FDA’s pre-license inspection of Immunitybio’s third-party contract manufacturing organizations, the company said. It said the FDA also had recommendations for specific chemistry, manufacturing and controls issues and assays that needed to be resolved before the BLA can be approved.
S-Adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors have been described in an Insilico Medicine IP Ltd. patent as potentially useful for the treatment of cancer.
RSS
